SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALHC Shareholder Notice: Alignment Healthcare Under Investigation for Potential Securities Fraud over Alleged Misrepresentations to Investors

ALHC Shareholder Notice: Alignment Healthcare Under Investigation for Potential Securities Fraud over Alleged Misrepresentations to Investors ALHC Shareholder Notice: Alignment Healthcare Under Investigation for Potential Securities Fraud over Alleged Misrepresentations to InvestorsPR NewswireNEW...

ALHC Legal Notice: Alignment Healthcare Investors are Notified to Contact BFA Law About the Ongoing Securities Fraud Investigation

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud after its significant stock drop.If you invested in Alignment securities, you are encouraged to obtain additional information by visiting...

Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC

Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHCPR...

Alignment Healthcare (NASDAQ: ALHC) Increasingly Scrutinized Over H3815 Cut Points And CMS Bonus Eligibility - HBSS

Alignment Healthcare (NASDAQ: ALHC) Increasingly Scrutinized Over H3815 Cut Points And CMS Bonus Eligibility - HBSS Alignment Healthcare (NASDAQ: ALHC) Increasingly Scrutinized Over H3815 Cut Points And CMS Bonus Eligibility - HBSSPR NewswireSAN FRANCISCO, Oct. 30, 2026 SAN FRANCISCO, Oct. 30, 2026...

Alignment Healthcare Q3 2026 Earnings Call Transcript

Alignment Healthcare (NASDAQ:ALHC) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...

Alignment Healthcare (ALHC) Reports Q3 Loss, Beats Revenue Estimates

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 0.00% and +3.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's What Key Metrics Tell Us About Alignment Healthcare (ALHC) Q3 Earnings

The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ALHC Investor Investigation: Alignment Healthcare Investors Are Alerted to the Securities Fraud Investigation after Inflated EBITDA Leads to 16% Stock Drop

ALHC Investor Investigation: Alignment Healthcare Investors Are Alerted to the Securities Fraud Investigation after Inflated EBITDA Leads to 16% Stock Drop ALHC Investor Investigation: Alignment Healthcare Investors Are Alerted to the Securities Fraud Investigation after Inflated EBITDA Leads to...

Analysts Estimate Alignment Healthcare (ALHC) to Report a Decline in Earnings: What to Look Out for

Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALHC Stock Drop Alert: BFA Law Announces Securities Fraud Investigation Into Alignment Healthcare Following Alleged Adjusted EBITDA Manipulation

• Reported GAAP EPS of -$0.04 down -300.00% YoY
• Reported revenue of $1.36B up 36.69% YoY
• Alignment Healthcare raised FY2026 health plan membership guidance to 305M and revenue to $5.25B, while lowering adjusted gross profit guidance to $575M and adjusted EBITDA to $100M.

Alignment Healthcare reported an increased adjusted MBR and lower Q3 adjusted EBITDA, lowered FY2026 adjusted-profit guidance, and cited risks in accurately estimating, pricing for, and managing medical costs and utilization.

Alignment Healthcare reported 36.7% year-over-year revenue growth and 31.2% membership growth, 11.6% adjusted gross profit growth, and nine-month net income of $39.9M versus $10M.

Alignment Healthcare, Inc. is a holding company, which offers a consumer-centric platform that delivers customized health care solutions to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. It offers health plan options through Alignment Health Plan, and partners with select health plans to help deliver better benefits at lower costs. The company was founded by John E. Kao in 2013 and is headquartered in Orange, CA.

Alignment Healthcare Inc

HUM Stock Soars, ALHC Sinks As CMS Star Ratings Redraw 2028 Bonuses

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Alignment Healthcare’s largest California contract, H3815, fell from 4 stars to 3.5.</li><li>Aetna said more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, and President Steve Nelson said the results “highlight our distinction in the market.”</li><li>Crossing 4 on CMS star rating unlocks bonus payments that raise the federal money an insurer receives per member.</li></ul><p>Humana (HUM) shares surged as much as 13% in after-hours trading Thursday after the Centers for Medicare &amp; Medicaid Services released 2027 Medicare Advantage star ratings, a quality scorecard that decides which plans earn extra federal bonus payments, while Alignment Healthcare (ALHC) tumbled 23% after its largest contract fell below that cutoff.</p><p>CVS Health fell about 3% in extended trading, and Clover Health rose about 10%.</p><h2 class="st-heading-2">Why The Stars Move The Stocks</h2><p>Medicare Advantage is the private version of Medicare. CMS scores each contract from 1 to 5 stars on measures such as clinical outcomes, member experience, and how the plan is run. The 4-star mark is the cutoff that matters to investors. Crossing it unlocks bonus payments that raise the federal money an insurer receives per member. Dropping below it takes that bonus away.</p><p>The ratings published Thursday do not change this year’s results. They feed payments in 2028, which is why a single half-star move on a large contract can be worth hundreds of millions of dollars.</p><h2 class="st-heading-2">Humana Clears The Bonus Line</h2><p>Humana was the clearest winner. Its largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold, CMS data showed.</p><p>The rebound matters because Humana was hit hard the last time CMS published ratings. In October 2024, the share of its members in plans rated 4 stars or higher fell from 94% to 25%, after a large contract dropped from 4.5 stars to 3.5. That cut the bonus payments the company was set to receive in 2026. Thursday’s recovery puts that large contract back in line for bonuses in 2028.</p><h2 class="st-heading-2">Alignment And CVS Lose Ground</h2><p>Alignment Healthcare moved the other way. Its largest California contract, H3815, fell from 4 stars to 3.5. That contract accounted for about 81% of membership, so the downgrade knocked most of the company off the bonus list even though six of its seven rated contracts still scored 4 stars or higher, including three at 4.5. Dawn Maroney, president of Alignment Health, said the California rating “is inconsistent with that performance” and that the company “intend[s] to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review,” while remaining confident it can return the contract to at least 4 stars.</p><p>CVS, through its Aetna unit, also lost ground. Aetna said more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, and President Steve Nelson said the results “highlight our distinction in the market” and give the company confidence it can return to “appropriate margins.” The smaller stock move reflected a broader book than Alignment’s, so a slip on part of it does not rewrite the whole company’s 2028 revenue.</p><p>Clover Health said CMS gave the plans covering about 98% of its members a 5-star rating for 2027, the score that sets 2028 payments. A smaller plan scored 4.5 stars. The 5-star score leaves out 20 measures a federal judge told CMS not to count in a May ruling that the agency has appealed. With those measures included, Clover said, the larger plans would have scored 4.5 stars.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around HUM and ALHC was 'bullish' at the time of writing.</p><p>While <a class="mention" data-mention="$HUM" data-symbol-id="HUM" href="https://stocktwits.com/symbol/HUM" target="_blank">HUM stock</a> has gained 51% year-to-date, CVS added 11%, and CLOV 95%. ALHC, in the meantime, has fallen 56%</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/t-tmus-vz-stocks-plunge-after-hours-as-space-x-buys-800-m-hz-spectrum-for-starlink-mobile/cZDUxmJRBV5">T, TMUS, VZ Stocks Plunge After-Hours As SpaceX Buys 800 MHz Spectrum For Starlink Mobile</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 Stethoscope with medicare form with parts list. Source: Getty Images

Humana’s largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold.

Clover Health Investments Corp

CVS Health Corp

Humana Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$7.28
Prev Close	$7.34
Open	$7.41
Dividend Yield	0.00%
50-Day Moving Average	$9.27
Beta	0.41
Avg. Volume	8.78M
PE Ratio	56.37

52-Week High	$25.12
52-Week Low	$6.01
Market Capitalization	$1.54B
EPS (Annual)	-$0.0037
Price to Book	5.54
Revenue Per Employee	$2.14M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALHC Fundamentals